{
  "abstract": "Objective To evaluate the effects of litifilimab on skin- and joint-specific outcomes in adults with SLE using LILAC Part A (phase II) data.Methods Prespecified and exploratory analyses were conducted in modified intent-to-treat population subsets from LILAC Part A (n=64 and n=56 for litifilimab 450 mg and placebo, respectively) with active skin and/or joint disease at baseline. Analyses included Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)-50 and CLASI-70, defined as ≥50%/70% improvement from baseline in CLASI-Activity (CLASI-A) score, at week 24 (baseline CLASI-A score ≥8; n=39 vs n=38); week 24 Joint-50 response (50% reduction in active joint counts; baseline ≥4 tender and ≥4 swollen joints; n=56 vs n=46); resolution of baseline SLE Disease Activity Index-2000 (SLEDAI-2K) skin rash and/or arthritis at week 24 and improvement by ≥1 grade from baseline to week 24 in British Isles Lupus Assessment Group 2004 index (BILAG-2004) mucocutaneous and musculoskeletal domains (baseline Grade A/B).Results Greater proportions of participants achieved CLASI-50 and CLASI-70 responses at weeks 4, 8, 12, 16, 20 and 24 with litifilimab than placebo. Regardless of the active joint count definition, greater proportions of participants treated with litifilimab achieved a Joint-50 response at week 24 than placebo (total tender plus total swollen joints, 78.6% vs 54.4%; total tender and/or swollen joints, 75.0% vs 52.2%; total tender and swollen joints, 83.9% vs 63.0%). At week 24, for litifilimab versus placebo, more participants had resolution of SLEDAI-2K rash (28.6% vs 10.7%), arthritis (48.2% vs 21.7%), rash and arthritis (23.0% vs 9.6%), and improvement of ≥1 grade in the BILAG-2004 mucocutaneous and musculoskeletal domains (50.0% vs 34.1%).Conclusions These findings characterise litifilimab’s effects on skin and joints and complement the LILAC Part A primary efficacy results, supporting the benefit of litifilimab for skin and joint manifestations in SLE.Trial registration number NCT02847598.",
  "abstract_shown": true,
  "affiliations": [
    "Amsterdam University Medical Centers, Amsterdam, The Netherlands",
    "Department of Rheumatology and Immunology, Semmelweis University, Budapest, Hungary",
    "Northwell Health, Great Neck, New York, USA",
    "University of California San Diego, La Jolla, California, USA",
    "University of Pennsylvania, Perelman School of Medicine and Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA",
    "Biogen, Cambridge, Massachusetts, USA",
    "Biogen, Baar, Switzerland"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Ronald F van Vollenhoven",
      "orcid": "0000-0001-6438-8663"
    },
    {
      "affs": [
        2
      ],
      "name": "Richard A Furie",
      "orcid": "0000-0001-6712-1585"
    },
    {
      "affs": [
        3
      ],
      "name": "Kenneth Kalunian"
    },
    {
      "affs": [
        4
      ],
      "name": "Victoria P Werth",
      "orcid": "0000-0001-5396-4362"
    },
    {
      "affs": [
        5
      ],
      "name": "Jessica Kong"
    },
    {
      "affs": [
        6
      ],
      "name": "Catherine Barbey",
      "orcid": "0000-0001-9870-3561"
    },
    {
      "affs": [
        5
      ],
      "name": "Youmna Lahoud",
      "orcid": "0000-0002-5677-3665"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/ck1bymqkmbr17.bib",
  "cited_by": 0,
  "doi": "10.1136/lupus-2026-002159",
  "fulltext_url": "https://lupus.bmj.com/content/13/2/e002159.full",
  "id": "ck1bymqkmbr17",
  "issns": [
    "2053-8790"
  ],
  "landing_url": "https://doi.org/10.1136/lupus-2026-002159",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "1506"
    ],
    [
      "heading",
      "2250"
    ],
    [
      "heading",
      "Clinical Trials and Drug Discovery"
    ],
    [
      "heading",
      "Original Research"
    ],
    [
      "lcc",
      "RC581-607"
    ]
  ],
  "openalex": null,
  "pdf_url": null,
  "pmcid": "PMC13735402",
  "pmid": "42971599",
  "published": "2026-11-02",
  "publisher": "BMJ Publishing Group",
  "ris": "https://research.draconitic.com/paper/ck1bymqkmbr17.ris",
  "sources": [
    {
      "first_seen": "2026-11-02T14:21:15Z",
      "native_id": "0886cb56c41449aaa8b02380c3d522f0",
      "source": "doaj",
      "url": "https://doi.org/10.1136/lupus-2026-002159"
    },
    {
      "first_seen": "2026-11-09T12:21:05Z",
      "native_id": "PMC13735402",
      "source": "pmc",
      "url": "https://doi.org/10.1136/lupus-2026-002159"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "lcc:RC581-607",
      "subfield": "general"
    }
  ],
  "title": "Litifilimab reduces skin and joint disease in participants with SLE: additional results from Part A of the phase II LILAC study",
  "title_text": "Litifilimab reduces skin and joint disease in participants with SLE: additional results from Part A of the phase II LILAC study",
  "type": "peer-reviewed",
  "updated_at": "2026-11-09T12:21:05Z",
  "url": "https://research.draconitic.com/paper/ck1bymqkmbr17",
  "venue": "Lupus Science and Medicine",
  "versions": []
}